Atlas Trials

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Clinical trial NCT06388083 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06388083
Sponsor
Belite Bio, Inc
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
STGD1Stargardt Disease 1
Start date
2024-07-31
Primary completion
2028-02-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.